Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Xencor Inc XNCR

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Bullboard (NDAQ:XNCR)

View:
Post by whytestockson Dec 02, 2024 2:46pm

Overweight Recommendation Issued On XNCR By Piper Sandler

Just In: $XNCR Overweight Recommendation Issued On XNCR By Piper Sandler2024-12-02 05:15:02 ET Piper Sandler analyst issues OVERWEIGHT recommendation for XNCR on December 2, 2024 08:43AM ET. XNCR was ...more  
Post by MikeTesteron Aug 02, 2024 5:24am

Xencor, Inc. (NASDAQ:XNCR): Advancing a Robust Bispecific Pi

https://beyondspx.com/2024/08/01/xencor-inc-nasdaqxncr-advancing-a-robust-bispecific-pipeline-with-promising-prostate-cancer-data/
Post by whytestockson Apr 09, 2024 11:00pm

Xencor Appoints Bart Cornelissen as Chief Financial Officer

JUST IN: $XNCR Xencor Appoints Bart Cornelissen as Chief Financial OfficerXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...more  
Post by ScarletteBourneon Nov 17, 2021 10:05am

🎉📣FSD Pharma's Research and Clinical Advisory Board📢

Dr. Eleanor N. Fish, a world-renowned immunologist and cytokine expert, has been appointed to FSD Pharma's Research and Clinical Advisory Board. FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities